Endocan: A novel inflammatory indicator in cardiovascular disease?

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 339-343

  Balta, Sevket ^a   Mikhailidis, Dimitri P ^b   Demirkol, Sait ^a   Ozturk, Cengiz ^a   Celik, Turgay ^a   Iyisoy, Atila ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atherosclerosis; Cell adhesion; Endocan; Endothelial dysfunction; Inflammation

Indexed keywords

BIOLOGICAL MARKER; ENDOCAN; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CELL ADHESION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM; BLOOD; METABOLISM;

BIOMARKERS; CARDIOVASCULAR DISEASES; CELL ADHESION; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; NEOPLASM PROTEINS; PROTEOGLYCANS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943576702     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.09.030     Document Type: Review

References (46)

1. Balta S., Ozturk C. The relation between CD40 ligand and coronary artery disease. Cardiology 2015, 131:107-108. 10.1159/000381180.
2. Balta I., Balta S., Demirkol S., Celik T., Ekiz O., Cakar M., et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2014, 65:74-78. 10.1177/0003319713485805.
3. Karaman M., Balta S., Ay S.A., Cakar M., Naharci I., Demirkol S., et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin. Exp. Hypertens. 2013, 35:516-522. 10.3109/10641963.2012.758734.
4. Altun B., Bulucu F., Demirbas S., Karaman M., Ay S.A., Cakar M., et al. The relationship between some of the cardiovascular risk factors and arterial stiffness parameters in essentially hypertensive patients. Clin. Exp. Hypertens. 2013, 35:444-448. 10.3109/10641963.2012.746354.
5. Sarrazin S., Adam E., Lyon M., Depontieu F., Motte V., Landolfi C., et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta 2006, 1765:25-37. 10.1016/j.bbcan.2005.08.004.
6. Kali A., Shetty K.S.R. Endocan: a novel circulating proteoglycan. Indian J. Pharmacol. 2014, 46:579-583. 10.4103/0253-7613.144891.
7. Lee H.G., Choi H.Y., Bae J.-S. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int. 2014, 86:1079-1081. 10.1038/ki.2014.292.
8. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone M.A., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999, 398:718-723. 10.1038/19546.
9. Balta S., Demirkol S., Celik T., Kucuk U., Unlu M., Arslan Z., et al. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology 2013, 64:627-632. 10.1177/0003319713480424.
10. Stéphane S., Claude-Alain M., Dominique D., Philippe L., Maryse D. Endocan as a biomarker of endothelial dysfunction in cancer. Diabetes Vasc. Dis. Res. 2010, 02:47-52. 10.4172/1948-5956.1000022.
11. Scherpereel A., Depontieu F., Grigoriu B., Cavestri B., Tsicopoulos A., Gentina T., et al. Endocan, a new endothelial marker in human sepsis. Crit. Care Med. 2006, 34:532-537.
12. Balta I., Balta S., Koryurek O.M., Demirkol S., Mikhailidis D.P., Celik T., et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J. Am. Acad. Dermatol. 2014, 70:291-296. 10.1016/j.jaad.2013.09.013.
13. Balta I., Balta S., Demirkol S., Mikhailidis D.P., Celik T., Akhan M., et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br. J. Dermatol. 2013, 169:1066-1070. 10.1111/bjd.12525.
14. Delehedde M., Devenyns L., Maurage C.-A., Vivès R.R. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int. J. Cell Biol. 2013, 2013:705027. 10.1155/2013/705027.
15. Balta S., Mikhailidis D.P., Demirkol S., Celik T., Ozturk C., Iyisoy A. Endocan and atherosclerosis. Angiology 2015, 66:490. 10.1177/0003319715568973.
16. Balta S., Balta I., Demirkol S., Ozturk C., Demir M. Endothelial function and Behçet disease. Angiology 2014, 65:657-659. 10.1177/0003319713513146.
17. Fotis L., Agrogiannis G., Vlachos I.S., Pantopoulou A., Margoni A., Kostaki M., et al. Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model. In Vivo 2012, 26:243-250.
18. Balta I., Balta S., Koryurek O.M., Demirkol S., Celik T., Akbay G., et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet's disease without significant cardiovascular involvement. J. Eur. Acad. Dermatol. Venereol. 2014, 28:1388-1393. 10.1111/jdv.12297.
19. Lee W., Ku S.-K., Kim S.-W., Bae J.-S. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J. Cell Physiol. 2014, 229:620-630. 10.1002/jcp.24485.
20. Menon P., Kocher O., Aird W. Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation 2011, 124:A15455.
21. Béchard D., Scherpereel A., Hammad H., Gentina T., Tsicopoulos A., Aumercier M., et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J. Immunol. 2001, 167:3099-3106.
22. Kose M., Emet S., Akpinar T.S., Kocaaga M., Cakmak R., Akarsu M., et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2014, (in press). 10.1177/0003319714548870.
23. Unlu M., Karaman M., Ay S.A., Balta S., Cakar M., Demirkol S., et al. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin. Exp. Hypertens. 2013, 35:418-423. 10.3109/10641963.2012.739237.
24. Wang X.-S., Yang W., Luo T., Wang J.-M., Jing Y.-Y. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet. Test. Mol. Biomark. 2015, 19:124-127. 10.1089/gtmb.2014.0274.
25. Balta S., Mikhailidis D.P., Demirkol S., Ozturk C., Kurtoglu E., Demir M., et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014, 65:773-777. 10.1177/0003319713513492.
26. Celik T., Balta S., Karaman M., Ahmet Ay S., Demirkol S., Ozturk C., et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press 2014, 1-6. 10.3109/08037051.2014.972816.
27. Tadzic R., Mihalj M., Vcev A., Ennen J., Tadzic A., Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013, 37:103-115. 10.1159/000350064.
28. Lee G.-K., Lee L.-C., Chong E., Lee C.-H., Teo S.-G., Chia B.-L., et al. The long-term predictive value of the neutrophil-to-lymphocyte ratio in type 2 diabetic patients presenting with acute myocardial infarction. QJM 2012, 105:1075-1082. 10.1093/qjmed/hcs123.
29. Balta S., Cakar M., Demirkol S., Kurt O., Unlu M., Kucuk U. The relationship between ankle-brachial index and estimated glomerular filtration rate in type 2 diabetes. Angiology 2013, 64:242. 10.1177/0003319712470560.
30. Tziomalos K., Athyros V.G., Karagiannis A., Mikhailidis D.P. Lipid lowering agents and the endothelium: an update after 4 years. Curr. Vasc. Pharmacol. 2012, 10:33-41.
31. Yilmaz M.I., Siriopol D., Saglam M., Kurt Y.G., Unal H.U., Eyileten T., et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014, 86:1213-1220. 10.1038/ki.2014.227.
32. Pawlak K., Mysliwiec M., Pawlak D. Endocan - the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clin. Biochem. 2015, 48:425-430. 10.1016/j.clinbiochem.2015.01.006.
33. Bechard D., Meignin V., Scherpereel A., Oudin S., Kervoaze G., Bertheau P., et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J. Vasc. Res. 2000, 37:417-425. 10.1159/000025758.
34. Balta S., Ozturk C. Endocan obstructive sleep apnea, and vascular risk. Angiology 2015, (in press). 10.1177/0003319715591332.
35. Altintas N., Mutlu L.C., Akkoyun D.C., Aydin M., Bilir B., Yilmaz A., et al. Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology 2015, (in press). 10.1177/0003319715590558.
36. Zhang S.M., Zuo L., Zhou Q., Gui S.Y., Shi R., Wu Q., et al. Expression and distribution of endocan in human tissues. Biotech. Histochem. 2012, 87:172-178. 10.3109/10520295.2011.577754.
37. Balta I., Akbay G., Kalkan G., Eksioglu M. Demographic and clinical features of 521 Turkish patients with Behçet's disease. Int. J. Dermatol. 2014, 53:564-569. 10.1111/j.1365-4632.2012.05756.x.
38. Ekiz O., Balta I., Sen B.B., Rifaioglu E.N., Ergin C., Balta S., et al. Mean platelet volume in recurrent aphthous stomatitis and Behçet disease. Angiology 2014, 65:161-165. 10.1177/0003319713492375.
39. Balta I., Balta S., Demirkol S., Celik T., Ekiz O., Cakar M., et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2013, 10.1177/0003319713485805.
40. Balanescu P., Ladaru A., Balanescu E., Voiosu T., Baicus C., Dan G. Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J. Clin. Lab. Anal. 2015, (in press). 10.1002/jcla.21864.
41. Tang L., Zhao Y., Wang D., Deng W., Li C., Li Q., et al. Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Mediat. Inflamm. 2014, 2014:625180. 10.1155/2014/625180.
42. Mosevoll K.A., Lindås R., Wendelbo O., Bruserud O., Reikvam H. Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. SpringerPlus 2014, 3:571. 10.1186/2193-1801-3-571.
43. Mihajlovic D.M., Lendak D.F., Brkic S.V., Draskovic B.G., Mitic G.P., Novakov Mikic A.S., et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc. Res. 2014, 93:92-97. 10.1016/j.mvr.2014.04.004.
44. Abid M.R., Yi X., Yano K., Shih S.-C., Aird W.C. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc. Res. 2006, 72:136-145. 10.1016/j.mvr.2006.05.010.
45. Cesarman-Maus G., Meillón L., Volkow P., Vargas-Ruiz A.G., Cornejo P., López-Navarro O., et al. Treatment of cancer and thrombosis: practical approach. Rev. Invest. Clin. 2013, 65:174-182.
46. Matano F., Yoshida D., Ishii Y., Tahara S., Teramoto A., Morita A. Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J. Neurooncol. 2014, 117:485-491. 10.1007/s11060-014-1377-6.